pSivida gets Austrian approval for eye drug; IntelGenx starts trials for migraine film;

 @DamianFierce: Tamarisk plans to "turn the industry upside down" with oral insulin platform. News | Follow @DamianFierce

> pSivida ($PSDV) has received marketing authorization in Austria for Iluvien, a treatment for vision impairment using the company's back-of-the-eye delivery platform. The approval is a step toward EMA approval, the company said. Release

> IntelGenx has launched trials for VersaFilm, its anti-migraine oral film, in Canada. The goal is to establish safety and bioequivalency for a future FDA application. More

> PCI Biotech has partnered with Modulight to develop a medical laser system to trigger endosomal drug release into cancerous cells. Report

> An Army researcher has discovered a new way to carry vaccines that could have drug delivery implications. Article

Suggested Articles

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.